

Eric D Bateman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4820265/publications.pdf>

Version: 2024-02-01

141
papers

21,959
citations

16411

64
h-index

11030

137
g-index

142
all docs

142
docs citations

142
times ranked

14573
citing authors

#	ARTICLE	IF	CITATIONS
1	International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. European Respiratory Journal, 2014, 43, 343-373.	3.1	2,898
2	An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 59-99.	2.5	1,591
3	Can Guideline-defined Asthma Control Be Achieved?. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 836-844.	2.5	1,489
4	Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health, 2012, 12, 204.	1.2	1,106
5	Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine, 2015, 3, 355-366.	5.2	937
6	Identifying "well-controlled" and "not well-controlled" asthma using the Asthma Control Questionnaire. Respiratory Medicine, 2006, 100, 616-621.	1.3	795
7	A summary of the new GINA strategy: a roadmap to asthma control. European Respiratory Journal, 2015, 46, 622-639.	3.1	636
8	Budesonide/Formoterol Combination Therapy as Both Maintenance and Reliever Medication in Asthma. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 129-136.	2.5	593
9	Tiotropium in Asthma Poorly Controlled with Standard Combination Therapy. New England Journal of Medicine, 2012, 367, 1198-1207.	13.9	578
10	Inhaled Combined Budesonide/Formoterol as Needed in Mild Asthma. New England Journal of Medicine, 2018, 378, 1865-1876.	13.9	453
11	COPD in Never Smokers. Chest, 2011, 139, 752-763.	0.4	444
12	Roflumilast"an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet, The, 2005, 366, 563-571.	6.3	443
13	A 6-Month, Placebo-Controlled Study Comparing Lung Function and Health Status Changes in COPD Patients Treated With Tiotropium or Salmeterol. Chest, 2002, 122, 47-55.	0.4	428
14	Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respiratory Medicine, 2016, 4, 781-796.	5.2	398
15	As-Needed Budesonide/Formoterol versus Maintenance Budesonide in Mild Asthma. New England Journal of Medicine, 2018, 378, 1877-1887.	13.9	368
16	Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. European Respiratory Journal, 2013, 42, 1484-1494.	3.1	358
17	Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD) Tj ETQq1 1 0.784314 rgBT /Overl	3.1	294
18	Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol/fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respiratory Medicine, 2013, 1, 51-60.	5.2	279

#	ARTICLE	IF	CITATIONS
19	GINA 2019: a fundamental change in asthma management. <i>European Respiratory Journal</i> , 2019, 53, 1901046.	3.1	277
20	Task shifting of antiretroviral treatment from doctors to primary-care nurses in South Africa (STRETCH): a pragmatic, parallel, cluster-randomised trial. <i>Lancet, The</i> , 2012, 380, 889-898.	6.3	243
21	Overall asthma control: The relationship between current control and future risk. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, 600-608.e6.	1.5	219
22	Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes. <i>European Respiratory Journal</i> , 2022, 59, 2102730.	3.1	218
23	Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 17-35.	2.5	196
24	Chronic obstructive pulmonary disease mortality and prevalence: the associations with smoking and poverty—a BOLD analysis. <i>Thorax</i> , 2014, 69, 465-473.	2.7	190
25	Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 315-322.	1.5	185
26	Improving lung health in low-income and middle-income countries: from challenges to solutions. <i>Lancet, The</i> , 2021, 397, 928-940.	6.3	176
27	The Global Initiative for Asthma (GINA): 25 years later. <i>European Respiratory Journal</i> , 2019, 54, 1900598.	3.1	174
28	Within-Subject Variability and Boosting of T-Cell Interferon- γ Responses after Tuberculin Skin Testing. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 49-58.	2.5	169
29	Efficacy and safety of twice-daily acclidinium bromide in COPD patients: the ATTAIN study. <i>European Respiratory Journal</i> , 2012, 40, 830-836.	3.1	168
30	Tuberculosis associates with both airflow obstruction and low lung function: BOLD results. <i>European Respiratory Journal</i> , 2015, 46, 1104-1112.	3.1	159
31	Efficacy and safety of acclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. <i>BMC Pulmonary Medicine</i> , 2014, 14, 178.	0.8	156
32	Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials. <i>Lancet Respiratory Medicine</i> , 2015, 3, 367-376.	5.2	153
33	Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the UK: a retrospective study of a clinical cohort. <i>Lancet Respiratory Medicine</i> , 2014, 2, 267-276.	5.2	149
34	Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. <i>Thorax</i> , 2012, 67, 781-788.	2.7	147
35	The asthma-COPD overlap syndrome: towards a revised taxonomy of chronic airways diseases?. <i>Lancet Respiratory Medicine</i> , 2015, 3, 719-728.	5.2	142
36	Efficacy of Varenicline Combined With Nicotine Replacement Therapy vs Varenicline Alone for Smoking Cessation. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 155.	3.8	135

#	ARTICLE	IF	CITATIONS
37	Tiotropium add-on therapy in adolescents with moderate asthma: A 1-year randomized controlled trial. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 441-450.e8.	1.5	133
38	The paradoxes of asthma management: time for a new approach?. <i>European Respiratory Journal</i> , 2017, 50, 1701103.	3.1	130
39	Roflumilast with long-acting β_2 -agonists for COPD: influence of exacerbation history. <i>European Respiratory Journal</i> , 2011, 38, 553-560.	3.1	117
40	A Systematic Review of the Association between Pulmonary Tuberculosis and the Development of Chronic Airflow Obstruction in Adults. <i>Respiration</i> , 2013, 86, 76-85.	1.2	116
41	Alternative mechanisms for tiotropium. <i>Pulmonary Pharmacology and Therapeutics</i> , 2009, 22, 533-542.	1.1	109
42	A guide to the translation of the Global Initiative for Asthma (GINA) strategy into improved care. <i>European Respiratory Journal</i> , 2012, 39, 1220-1229.	3.1	105
43	Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 864-879.	1.5	103
44	Integrating real-life studies in the global therapeutic research framework. <i>Lancet Respiratory Medicine</i> , 2013, 1, e29-e30.	5.2	102
45	Acclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and) Tj ETQq1 1 0.784314 rgBTz/Ove		
46	Meta-analysis: Effects of Adding Salmeterol to Inhaled Corticosteroids on Serious Asthma-Related Events. <i>Annals of Internal Medicine</i> , 2008, 149, 33.	2.0	97
47	Fevipirant, an oral prostaglandin DP ₂ receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids. <i>European Respiratory Journal</i> , 2017, 50, 1700670.	3.1	93
48	Development and validation of a novel risk score for asthma exacerbations: The risk score for exacerbations. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 1457-1464.e4.	1.5	88
49	Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status. <i>Respiratory Medicine</i> , 2016, 117, 198-206.	1.3	87
50	Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. <i>Clinical and Translational Allergy</i> , 2019, 9, 44.	1.4	87
51	Efficacy and Safety of Fluticasone Furoate/Vilanterol Compared With Fluticasone Propionate/Salmeterol Combination in Adult and Adolescent Patients With Persistent Asthma. <i>Chest</i> , 2013, 144, 1222-1229.	0.4	86
52	Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 117, 563-570.	1.5	84
53	Efficacy and safety of roflumilast in the treatment of asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2006, 96, 679-686.	0.5	82
54	Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 32, 37-44.	1.1	78

#	ARTICLE	IF	CITATIONS
55	Combined Analysis of Asthma Safety Trials of Long-Acting β_2 -Agonists. <i>New England Journal of Medicine</i> , 2018, 378, 2497-2505.	13.9	76
56	Occupational allergy and asthma among salt water fish processing workers. <i>American Journal of Industrial Medicine</i> , 2008, 51, 899-910.	1.0	74
57	Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. <i>Thorax</i> , 2014, 69, 312-319.	2.7	73
58	Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial. <i>Thorax</i> , 2012, 67, 35-41.	2.7	72
59	Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma. <i>European Respiratory Journal</i> , 2014, 43, 773-782.	3.1	72
60	Determinants of response to fluticasone propionate and salmeterol/fluticasone propionate combination in the Gaining Optimal Asthma control study. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 120, 1036-1042.	1.5	71
61	Combination Therapy with Single Inhaler Budesonide/Formoterol Compared with High Dose of Fluticasone Propionate Alone in Patients with Moderate Persistent Asthma. <i>Treatments in Respiratory Medicine</i> , 2003, 2, 275-281.	1.4	69
62	High Prevalence of Tuberculosis in Previously Treated Patients, Cape Town, South Africa. <i>Emerging Infectious Diseases</i> , 2007, 13, 1189-1194.	2.0	69
63	Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β_2 -agonist vilanterol administered once daily for 52 weeks in patients ≥ 12 years old with asthma: a randomised trial. <i>Thorax</i> , 2013, 68, 513-520.	2.5	69
64	Airflow Obstruction and Use of Solid Fuels for Cooking or Heating. BOLD (Burden of Obstructive) Tj ETQq0 0 0 rgBTJ (Overlock 10 Tf 50	2.5	69
65	Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 589-596.e3.	2.0	69
66	Dose effect of once-daily fluticasone furoate in persistent asthma: A randomized trial. <i>Respiratory Medicine</i> , 2012, 106, 642-650.	1.3	67
67	Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, S1-S18.	2.0	66
68	Tiotropium Respimat Add-on Is Efficacious in Symptomatic Asthma, Independent of T2 Phenotype. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 923-935.e9.	2.0	64
69	Characterisation and impact of reported and unreported exacerbations: results from ATTAIN. <i>European Respiratory Journal</i> , 2014, 44, 1156-1165.	3.1	60
70	Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps. <i>Respiratory Research</i> , 2011, 12, 38.	1.4	58
71	Magnitude of effect of asthma treatments on Asthma Quality of Life Questionnaire and Asthma Control Questionnaire scores: Systematic review and network meta-analysis. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 914-922.	1.5	58
72	Overdiagnosis of COPD in Subjects With Unobstructed Spirometry. <i>Chest</i> , 2019, 156, 277-288.	0.4	57

#	ARTICLE	IF	CITATIONS
73	ARIA–EAACI statement on asthma and COVID‑19 (June 2, 2020). Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 689-697.	2.7	57
74	Prevalence and Population-Attributable Risk for Chronic Airflow Obstruction in a Large Multinational Study. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1353-1365.	2.5	52
75	AIRWAYS-ICPs (European Innovation Partnership on Active and Healthy Ageing) from concept to implementation. European Respiratory Journal, 2016, 47, 1028-1033.	3.1	50
76	Short-acting β_2 -agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study. European Respiratory Journal, 2022, 59, 2101402.	3.1	50
77	A randomized study comparing ciclesonide and fluticasone propionate in patients with moderate persistent asthma. Respiratory Medicine, 2007, 101, 1677-1686.	1.3	49
78	Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma. Journal of Allergy and Clinical Immunology, 2016, 138, 142-149.e8.	1.5	49
79	Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies. International Journal of COPD, 2010, 5, 197-208.	0.9	48
80	Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids. Annals of Allergy, Asthma and Immunology, 2012, 109, 353-358.e4.	0.5	47
81	Ciclesonide Reduces the Need for Oral Steroid Use in Adult Patients With Severe, Persistent Asthma. Chest, 2006, 129, 1176-1187.	0.4	46
82	ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 168-190.	2.7	46
83	Effect of a single day of increased as-needed budesonide–formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study. Lancet Respiratory Medicine, 2021, 9, 149-158.	5.2	46
84	Asthma management in low and middle income countries: case for change. European Respiratory Journal, 2022, 60, 2103179.	3.1	45
85	Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma. Respiratory Research, 2011, 12, 160.	1.4	42
86	Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial. Respiratory Research, 2011, 12, 132.	1.4	42
87	Fluticasone Furoate–Vilanterol 100-25 mcg Compared with Fluticasone Furoate 100 mcg in Asthma: A Randomized Trial. Journal of Allergy and Clinical Immunology: in Practice, 2014, 2, 553-561.	2.0	40
88	Efficacy and safety of fluticasone furoate 100‑4g once-daily in patients with persistent asthma: A 24-week placebo and active-controlled randomised trial. Respiratory Medicine, 2014, 108, 41-49.	1.3	37
89	Helsinki by nature: The Nature Step to Respiratory Health. Clinical and Translational Allergy, 2019, 9, 57.	1.4	36
90	Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPD. Pulmonary Pharmacology and Therapeutics, 2013, 26, 581-587.	1.1	35

#	ARTICLE	IF	CITATIONS
91	Fluticasone furoate (FF)/vilanterol (100/25µmcg or 200/25µmcg) or FF (100µmcg) in persistent asthma. <i>Journal of Asthma</i> , 2015, 52, 1073-1083.	0.9	35
92	A Practical Guide to Implementing SMART in Asthma Management. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, S31-S38.	2.0	34
93	Prevalence and Characteristics of Asthma-Chronic Obstructive Pulmonary Disease Overlap in Routine Primary Care Practices. <i>Annals of the American Thoracic Society</i> , 2019, 16, 1143-1150.	1.5	32
94	Safety and tolerability of once-daily tiotropium Respimat Â® as add-on to at least inhaled corticosteroids in adult patients with symptomatic asthma: A pooled safety analysis. <i>Respiratory Medicine</i> , 2016, 118, 102-111.	1.3	31
95	Global Initiative for Asthma Strategy 2021. <i>Respirology</i> , 2022, 27, 14-35.	1.3	31
96	Global Initiative for Asthma Strategy 2021. Executive Summary and Rationale for Key Changes. <i>Archivos De Bronconeumologia</i> , 2022, 58, 35-51.	0.4	31
97	Development of a South African integrated syndromic respiratory disease guideline for primary care. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2008, 17, 156-163.	2.5	30
98	Recent advances in COPD disease management with fixed-dose long-acting combination therapies. <i>Expert Review of Respiratory Medicine</i> , 2014, 8, 357-379.	1.0	30
99	The SYGMA programme of phase 3 trials to evaluate the efficacy and safety of budesonide/formoterol given "as needed"™ in mild asthma: study protocols for two randomised controlled trials. <i>Trials</i> , 2017, 18, 12.	0.7	30
100	What have we learnt about asthma control from trials of budesonide/formoterol as maintenance and reliever?. <i>Respirology</i> , 2020, 25, 804-815.	1.3	29
101	Rate of Response of Individual Asthma Control Measures Varies and May Overestimate Asthma Control: An Analysis of the Goal Study. <i>Journal of Asthma</i> , 2007, 44, 667-673.	0.9	28
102	Improvement in asthma endpoints when aiming for total control: salmeterol/fluticasone propionate versus fluticasone propionate alone. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2007, 16, 155-161.	2.5	26
103	Safety and Immunogenicity of Adenovirus 35 Tuberculosis Vaccine Candidate in Adults with Active or Previous Tuberculosis. A Randomized Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 1171-1180.	2.5	26
104	A randomized study of BI 671800, a CRTH2 antagonist, as add-on therapy in poorly controlled asthma. <i>Allergy and Asthma Proceedings</i> , 2017, 38, 157-164.	1.0	25
105	<p>Transition from Restrictive to Obstructive Lung Function Impairment During Treatment and Follow-Up of Active Tuberculosis</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 1039-1047.	0.9	25
106	Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom. <i>European Journal of Health Economics</i> , 2014, 15, 69-82.	1.4	23
107	Efficacy and safety of fluticasone furoate 100Â¼g and 200Â¼g once daily in the treatment of moderate-severe asthma in adults and adolescents: a 24-week randomised study. <i>BMC Pulmonary Medicine</i> , 2014, 14, 113.	0.8	22
108	Efficacy and Safety of As-Needed Budesonide-Formoterol in Adolescents with Mild Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3069-3077.e6.	2.0	22

#	ARTICLE	IF	CITATIONS
109	Efficacy and safety of once-daily fluticasone furoate 50 mcg in adults with persistent asthma: a 12-week randomized trial. <i>Respiratory Research</i> , 2014, 15, 88.	1.4	19
110	Lung function changes over time following withdrawal of inhaled corticosteroids in patients with severe COPD. <i>European Respiratory Journal</i> , 2016, 47, 651-654.	3.1	19
111	Comparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids. <i>Journal of Negative Results in BioMedicine</i> , 2014, 13, 9.	1.4	18
112	Efficacy and safety of the CRTh2 antagonist AZD1981 as add-on therapy to inhaled corticosteroids and long-acting β2-agonists in patients with atopic asthma. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 1093-1106.	2.0	18
113	Predicting Responders to Reslizumab after 16 Weeks of Treatment Using an Algorithm Derived from Clinical Studies of Patients with Severe Eosinophilic Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 489-495.	2.5	17
114	Positioning As-needed Budesonide–Formoterol for Mild Asthma: Effect of Prestudy Treatment in Pooled Analysis of SYGMA 1 and 2. <i>Annals of the American Thoracic Society</i> , 2021, 18, 2007-2017.	1.5	17
115	Severity of Airflow Obstruction in Chronic Obstructive Pulmonary Disease (COPD): Proposal for a New Classification. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2017, 14, 469-475.	0.7	16
116	Silicosis among gemstone workers in South Africa: Tiger's-eye pneumoconiosis. <i>American Journal of Industrial Medicine</i> , 1991, 19, 205-213.	1.0	15
117	Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma. <i>Respiratory Medicine</i> , 2022, 191, 105991.	1.3	13
118	As-Needed Budesonide–Formoterol in Mild Asthma. <i>New England Journal of Medicine</i> , 2018, 379, 897-898.	13.9	11
119	Treatment adherence in asthmatic patients: The last frontier?. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 1269-1270.	1.5	10
120	Global Initiative for Asthma 2016–derived asthma control with fluticasone propionate and salmeterol. <i>Annals of Allergy, Asthma and Immunology</i> , 2019, 123, 57-63.e2.	0.5	10
121	Chronic obstructive pulmonary disease mortality and prevalence: the associations with smoking and poverty: a BOLD analysis–authors–reply. <i>Thorax</i> , 2014, 69, 869.2-870.	2.7	9
122	Systems for the management of respiratory disease in primary care – an international series: South Africa. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2009, 18, 69-75.	2.5	8
123	ɪmp;#x2013;Randomized dose-finding study of batefenterol via dry powder inhaler in patients with COPDɪmp;#x2013;. <i>International Journal of COPD</i> , 2019, Volume 14, 615-629.	0.9	8
124	Safety of As-Needed Budesonide-Formoterol in Mild Asthma: Data from the Two Phase III SYGMA Studies. <i>Drug Safety</i> , 2021, 44, 467-478.	1.4	8
125	Chronic airflow obstruction and ambient particulate air pollution. <i>Thorax</i> , 2021, 76, 1236-1241.	2.7	7
126	QVA149 Improves Lung Function, Dyspnea, and Health Status Independent of Previously Prescribed Medications and COPD Severity: A Subgroup Analysis from the SHINE and ILLUMINATE Studies. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2014, 2, 48-60.	0.5	7

#	ARTICLE	IF	CITATIONS
127	Efficacy and safety of high-dose ciclesonide for the treatment of severe asthma. Expert Review of Respiratory Medicine, 2013, 7, 339-348.	1.0	6
128	Efficacy of budesonide/formoterol maintenance and reliever therapy compared with higher-dose budesonide as step-up from low-dose inhaled corticosteroid treatment. BMC Pulmonary Medicine, 2017, 17, 65.	0.8	6
129	Lung function defects in treated pulmonary tuberculosis patients. European Respiratory Journal, 2016, 47, 352-353.	3.1	5
130	Lung Diseases in South Africa: An Overview. Novartis Foundation Symposium, 0, , 4-16.	1.2	5
131	Asthma attacks: how can we reduce the risks?. Npj Primary Care Respiratory Medicine, 2015, 25, 14105.	1.1	4
132	Consistent improvement in health-related quality of life with tiotropium in patients with chronic obstructive pulmonary disease: Novel and conventional responder analyses. Respiratory Medicine, 2016, 120, 91-100.	1.3	4
133	Efficacy and safety of the long-acting muscarinic antagonist GSK233705 delivered once daily in patients with COPD. Clinical Respiratory Journal, 2012, 6, 248-257.	0.6	3
134	Salmeterol/Fluticasone Propionate Combination. Drugs, 1999, 57, 941-943.	4.9	1
135	Inhaled Triamcinolone Acetonide HFA 450??g Twice Daily Compared with Beclomethasone Dipropionate CFC 500??g Twice Daily in Adults with Moderate Persistent Asthma. Clinical Drug Investigation, 2000, 20, 9-17.	1.1	1
136	Integrated clinical management tools for respiratory diseases: lessons from PAL in sub-Saharan Africa. International Journal of Tuberculosis and Lung Disease, 2016, 20, 429-429.	0.6	1
137	Reply to: Cause or consequence?. European Respiratory Journal, 2022, 59, 2200103.	3.1	1
138	Comment on: "Cost Effectiveness of Tiotropium in Patients with Asthma Poorly Controlled on Inhaled Glucocorticosteroids and Long-Acting β_2 -Agonists". Applied Health Economics and Health Policy, 2016, 14, 117-118.	1.0	0
139	Response to the correspondence: "Non-optimal methodology questions indirect treatment comparison of dupilumab vs other biologics in severe asthma". Respiratory Medicine, 2022, 191, 106088.	1.3	0
140	Response to comment on: Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma (Respir. Med. 2020). Respiratory Medicine, 2022, 191, 106106.	1.3	0
141	Reply to "As-needed budesonide-formoterol for adolescents with mild asthma: importance of lung function". Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 4179-4180.	2.0	0